CClinicalTrials.gg
Sign In
CompletedNCT05539976Updated Dec 1, 2022

A Taste Assessment of Iberdomide and Mezigdomide in Healthy Participants

An observational study in Healthy Participants, sponsored by Bristol-Myers Squibb. Completed at 1 site in United States. Open to participants aged 25 Years to 80 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-12-01.

Sponsored by Bristol-Myers Squibb · Observational

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
10
Ages
25 Years to 80 Years
Sex
All
01

Study summary

The purpose of this study is to develop taste profiles of iberdomide and mezigdomide drug substances and oral formulation prototypes in order to develop a pediatric oral form of iberdomide and mezigdomide.

02

Conditions studied

  • Healthy Participants
03

In context

Lead sponsor

Bristol-Myers Squibb is the lead sponsor of 1,538 studies on the registry; 116 are open to participants now.

Of its 429 completed or terminated interventional studies of FDA-regulated products, 223 (52%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
25 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

The study population will consist of healthy volunteers who are qualified based on training and experience in performing taste evaluations.

Inclusion criteria

  • Participant is qualified based on training and experience.
  • Participants must be trained to detect, identify, recognize, and accurately describe different taste elements and flavor combinations. Training is initially accomplished by tasting model compounds and learning to recognize and describe these accurately. These abilities are then honed and refined through additional experience in performing taste profiling.
  • Participant is qualified based on training and experience.
  • Senopsys LLC will provide all participants.
  • Participants must be trained to detect, identify, recognize, and accurately describe different taste elements and flavor combinations. Training is initially accomplished by tasting model compounds and learning to recognize and describe these accurately. These abilities are then honed and refined through additional experience in performing taste profiling.

Exclusion criteria

Exclusion Criteria:

  • Participant has any history of any illness, medical condition, laboratory abnormality, or psychiatric illness that, in the opinion of the investigator, might confound the results of the study or places the participant at unacceptable risk if he or she were to participate in the study.
  • Participant has a known hypersensitivity to mezigdomide, iberdomide, thalidomide, lenalidomide, or pomalidomide.
  • Participant is a female that is pregnant, breastfeeding, or is a women of childbearing potential (WOCBP).
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
10 participants (actual)
Patient registry
No

Groups and cohorts

  • Healthy participants who perform taste evaluations

    A maximum of 10 healthy adult participants will complete a maximum of 30 taste assessment days, to evaluate the taste characteristics of iberdomide or mezigdomide on each taste assessment day.

06

What researchers measure

Primary outcomes

  1. Taste Evaluation - Aromatic Identity

    Time frame: Up to 3 Months

  2. Taste Evaluation - Amplitude

    Time frame: Up to 3 Months

  3. Taste Evaluation - Mouthfeel

    Time frame: Up to 3 Months

  4. Taste Evaluation - Off-notes

    Time frame: Up to 3 Months

  5. Taste Evaluation - Aftertaste

    Time frame: Up to 3 Months

07

Study locations

1 site
  • Local Institution - 0001
    Woburn, Massachusetts 01801-6353, United States
08

References and documents

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Dec 1, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05539976
Lead sponsor
Bristol-Myers Squibb
Responsible party
Sponsor
First posted
Sep 14, 2022
Start date
Sep 30, 2022
Primary completion
Nov 14, 2022
Completion
Nov 14, 2022
Last update
Dec 1, 2022

Study contacts

Bristol Myers Squibb
study director · Bristol-Myers Squibb

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies from this sponsor

Bristol-Myers Squibb

Start the discussion